Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?

To: Keith Feral who wrote (310)	10/1/2007 4:08:44 PM
From: estatemakr	Read Replies (1) \| Respond to of 418

Keith, If transfusional delivery is suboptimal, and bolus is the way to go, then why in the hell did Management structure the study this way, and Speak optimistically about it all of this time, and therefore set "the bar high" instead of forewarning of a possible transfusional delivery "issue"?? Why haven't we heard prior to today that this method might be "suboptimal"???? I appreciate prudence in management. Underpromise and overdeliver.......the exact opposite of what we got today!! Are they inept, fraudulent, or dillusional??

To: Keith Feral who wrote (310)	10/1/2007 4:34:03 PM
From: DewDiligence_on_SI	Read Replies (3) \| Respond to of 418

…infusional 5FU is not the gold standard for the delivery of 5FU and it's only used in third world countries like Serbia, Poland, and India… You have it backwards: infusional has all but supplanted bolus administration. Can you even find a state-of-the-art trial that uses bolus?